Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

13.05.2022 - FDA approval for EPSOLAY (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected until 2040Partner Galderma to launch two products in the U.S. this quarter: TWYNEO launched in ...

Related Keywords

United States ,Israel ,Americans ,Irina Koffler ,Gilad Mamlok ,Company Annual Report On Form ,Exchange Commission ,Gel Technologies Inc ,Recent Corporate ,Sol Gel Technologies ,Prescribing Information ,Inflammatory Lesions ,Private Securities Litigation Reform Act ,Annual Report ,